Skip to main content
. 2021 Sep 20;11:736678. doi: 10.3389/fonc.2021.736678

Table 1.

Demographics and clinical characteristics.

Characteristics No. of lymph nodes examined (%) p-value
<12 (n = 21,497) ≥12 (n = 58,799)
Race 0.013
 White 17,340 (80.7) 47,882 (81.4)
 Black 2,547 (11.8) 6,536 (11.1)
 Other 1,610 (7.5) 4381 (7.5)
Age at diagnosis <0.001
 ≤75 years 11,660 (54.2) 36,608 (62.3)
 >75 years 9,837 (45.8) 22,191 (37.7)
T stage 0.034
 T3 17,951 (83.5) 49,464 (84.1)
 T4 3,546 (16.5) 9,335 (15.9)
N stage <0.001
 N0 12,789 (59.5) 31,748 (54.0)
 N1 6,374 (29.7) 16,079 (27.3)
 N2 2,334 (10.9) 10,972 (18.7)
Tumor grade <0.001
 High/Moderate 16,700 (77.7) 43,430 (73.9)
 Poor/Anaplastic 4,328 (20.1) 14,318 (24.4)
 Unknown 469 (2.2) 1,051 (1.8)
Sex <0.001
 Male 10,575 (49.2) 27,962 (47.6)
 Female 10,922 (50.8) 30,837 (52.4)
Histology <0.001
 Adenocarcinoma 19,287 (89.7) 51,692 (87.9)
 Mucinous/signet ring cell 2,210 (10.3) 7,107 (12.1)
Year of diagnosis <0.001
 2004–2007 15,878 (73.9) 30,885 (52.5)
 2008–2010 5,619 (26.1) 27,914 (47.5)
Chemotherapy <0.001
 No 15,267 (71.0) 38,086 (64.8)
 Yes 6,230 (29.0) 20,713 (35.2)